Phillips T, Brunvand M, Chen AI, Essell J, et al. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study. Am J Hematol 2022;97:E24-E27.
PMID: 34731510